GenScript Biotech科技在2025年创下了创纪录的959.5百万元收入,上升61.4%,这得益于AI药物开发、生物需求和全球扩张。 GenScript Biotech hit record $959.5M revenue in 2025, up 61.4%, fueled by AI drug development, biologics demand, and global expansion.

GenScript Biotech Corp报告,创纪录的2025财政年度收入为9.595亿美元,年同比增长61.4%,其驱动因素是许可费提高、AI驱动的药物开发需求以及生物学CDMO市场的复苏。 GenScript Biotech Corp reported record fiscal year 2025 revenue of $959.5 million, a 61.4% increase year-on-year, driven by higher license fees, AI-driven drug development demand, and recovery in biologics CDMO markets. 调整后的净利润猛增285%,达到2.303亿美元,而毛利润上升103.3%,达到5.532亿美元。 Adjusted net profit surged 285% to $230.3 million, while gross profit rose 103.3% to $553.2 million. 由于在基因到蛋白质工作流程、全球扩张(特别是在欧洲和亚太)以及自动化升级方面的平台协同效应,促进了增长,目前60%的生产能力由AI驱动。 Growth was fueled by platform synergies in gene-to-protein workflows, global expansion—especially in Europe and Asia-Pacific—and automation upgrades, with 60% of production capacity now AI-driven. 增加研发和战略投资加强了其在生命科学工具、生物学和工业生物技术中的地位。 Increased R&D and strategic investments strengthened its position in life science tools, biologics, and industrial biotechnology.